Sheaff Brock Investment Advisors LLC Cuts Position in Eli Lilly and Co (LLY)

Sheaff Brock Investment Advisors LLC trimmed its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 6.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 32,202 shares of the company’s stock after selling 2,275 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Eli Lilly and were worth $2,720,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the period. BlackRock Inc. increased its holdings in Eli Lilly and by 1.2% during the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock valued at $5,393,119,000 after buying an additional 776,893 shares during the period. Janus Henderson Group PLC increased its holdings in Eli Lilly and by 16.1% during the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after buying an additional 1,503,918 shares during the period. UBS Asset Management Americas Inc. increased its holdings in Eli Lilly and by 1.8% during the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock valued at $560,509,000 after buying an additional 115,499 shares during the period. Finally, Dodge & Cox increased its holdings in Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the period. 75.71% of the stock is currently owned by institutional investors.

LLY has been the topic of several research reports. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a report on Tuesday, January 16th. Goldman Sachs Group lowered shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $86.98 to $95.00 in a report on Tuesday, January 16th. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the company from $85.52 to $115.00 in a report on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Finally, Bank of America cut their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $93.22.

Eli Lilly and Co (LLY) opened at $77.20 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09. The stock has a market cap of $84,963.62, a price-to-earnings ratio of -384.73, a price-to-earnings-growth ratio of 1.45 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.95 earnings per share. sell-side analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.91%. Eli Lilly and’s payout ratio is -1,124.94%.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the sale, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Insiders have sold 259,610 shares of company stock worth $22,727,406 over the last three months. Corporate insiders own 0.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sheaff Brock Investment Advisors LLC Cuts Position in Eli Lilly and Co (LLY)” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://weekherald.com/2018/02/22/sheaff-brock-investment-advisors-llc-cuts-position-in-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply